The invention, applied in the clinical field, has the function of characterizing a specific genetic trait of patients affected by some tumoral pathologies (such as colon or breast cancer), with the aim of improving the prognosis and the choice of an optimal therapy.
Patent title | PCR Primer designed for genotyping of ODC1 +316 A/G SNP in patients affected by cancer deseases. |
---|---|
Thematic area | Health |
Ownership | ALMA MATER STUDIORUM - UNIVERSITA' DI BOLOGNA |
Inventors | Paolo Pigini, Giovanni Perini |
Protection | Italy |
Licensing status | Available for licensing agreements |
Keywords | ODC1, SNP, primer, Allele-specific, Genotyping |
Filed on | 16 January 2020 |
Some genetic traits can influence disease outcome. The mentioned genetic trait, known as "ODC1 +316 A / G SNP", has been associated with survival of patients with colon or breast cancer. Its characterization is therefore important to recognize the tumor aggressiveness and subsequently to choose an appropriate therapy.
The technology consists of DNA molecules specifically designed to be used in clinical analysis techniques (called PCR) for the characterization of the mentioned genetic trait in patients’ DNA samples.
This type of technology is commonly applied in clinical analysis laboratories. However, there is currently no product specifically designed for the mentioned genetic trait ("ODC1 +316 A / G SNP"), for which less efficient and more expensive technologies are the only available option. The clinical methodology would therefore benefit from a substantial improvement.